1. CooperD, Gatell J, Rockstroh Jet al.: Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 105aLB).
2. SteigbigelR, Kumar P, Eron Jet al.: Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 105bLB).
3. NelsonM, Fätkenheuer G, Konourina Iet al.: Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 104aLB).
4. LalezariJ, Goodrich J, DeJesus Eet al.: Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a Phase 2b/3 study in the US and Canada.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 104bLB).
5. PozniakA, Morales-Ramirez J, Mohapi Let al.: 48-week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients.Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.Los Angeles, CA, USA, 25–28 February 2007 (Abstract 144LB).